Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: The role of interleukin 1.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 32646930.
- Also identified by DOI 10.3949/ccjm.87a.ccc044.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Interleukin 1 (IL-1) is a potential target of therapy in COVID-19 during the severe respiratory-inflammatory phase ("cytokine release syndrome"), when pulmonary macrophages are hyperactivated, releasing IL-1 and other cytokines. Preliminary evidence indicates that anakinra and canakinumab, drugs that block the action of IL-1 and have a good safety profile, improve the outcomes of patients with COVID-19 cytokine release syndrome. Results from large, randomized clinical trials are pending.